89 results on '"Lövey J"'
Search Results
2. Radiosensitivity of human prostate cancer cells can be modulated by inhibition of 12-lipoxygenase
- Author
-
Lövey, J., Nie, D., Tóvári, J., Kenessey, I., Tímár, J., Kandouz, M., and Honn, K.V.
- Published
- 2013
- Full Text
- View/download PDF
3. Evaluation of Metastatic Lymph Nodes by Means of FDG PET
- Author
-
Lövey, J., Ésik, O., Gulyás, B., Tóth, E., Molnár, T., Trón, L., Gulyás, Balázs, editor, and Müller-Gärtner, Hans W., editor
- Published
- 1998
- Full Text
- View/download PDF
4. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
- Author
-
Lee, N.Y. Ferris, R.L. Psyrri, A. Haddad, R.I. Tahara, M. Bourhis, J. Harrington, K. Chang, P.M.-H. Lin, J.-C. Razaq, M.A. Teixeira, M.M. Lövey, J. Chamois, J. Rueda, A. Hu, C. Dunn, L.A. Dvorkin, M.V. De Beukelaer, S. Pavlov, D. Thurm, H. Cohen, E.
- Abstract
Background: Chemoradiotherapy is the standard of care for unresected locally advanced squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab (anti-PD-L1) to chemoradiotherapy could improve treatment outcomes for this patient population. Methods: In this randomised, double-blind, placebo-controlled, phase 3 study, patients were recruited from 196 hospitals and cancer treatment centres in 22 countries. Patients aged 18 years or older, with histologically confirmed, previously untreated, locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, larynx, or oral cavity (unselected for PD-L1 status), an Eastern Cooperative Oncology Group performance status score of 0 or 1, and who could receive chemoradiotherapy were eligible. Patients were randomly assigned (1:1) centrally by means of stratified block randomisation with block size four (stratified by human papillomavirus status, tumour stage, and nodal stage, and done by an interactive response technology system) to receive 10 mg/kg avelumab intravenously every 2 weeks plus chemoradiotherapy (100 mg/m2 cisplatin every 3 weeks plus intensity-modulated radiotherapy with standard fractionation of 70 Gy [35 fractions during 7 weeks]; avelumab group) or placebo plus chemoradiotherapy (placebo group). This was preceded by a single 10 mg/kg avelumab or placebo lead-in dose given 7 days previously and followed by 10 mg/kg avelumab or placebo every 2 weeks maintenance therapy for up to 12 months. The primary endpoint was progression-free survival by investigator assessment per modified Response Evaluation Criteria in Solid Tumors, version 1.1, in all randomly assigned patients. Adverse events were assessed in patients who received at least one dose of avelumab or placebo. This trial is registered with ClinicalTrials.gov, NCT02952586. Enrolment is no longer ongoing, and the trial has been discontinued. Findings: Between Dec 12, 2016, and Jan 29, 2019, from 907 patients screened, 697 patients were randomly assigned to the avelumab group (n=350) or the placebo group (n=347). Median follow-up for progression-free survival was 14·6 months (IQR 8·5–19·6) in the avelumab group and 14·8 months (11·6–18·8) in the placebo group. Median progression-free survival was not reached (95% CI 16·9 months–not estimable) in the avelumab group and not reached (23·0 months–not estimable) in the placebo group (stratified hazard ratio 1·21 [95% CI 0·93–1·57] favouring the placebo group; one-sided p=0·92). The most common grade 3 or worse treatment-related adverse events were neutropenia (57 [16%] of 348 patients in the avelumab group vs 52 [15%] of 344 patients in the placebo group), mucosal inflammation (50 [14%] vs 45 [13%]), dysphagia (49 [14%] vs 47 [14%]), and anaemia (41 [12%] vs 44 [13%]). Serious treatment-related adverse events occurred in 124 (36%) patients in the avelumab group and in 109 (32%) patients in the placebo group. Treatment-related deaths occurred in two (1%) patients in the avelumab group (due to general disorders and site conditions, and vascular rupture) and one (
- Published
- 2021
5. Radiation-induced oral mucositis in head and neck cancer patients. Five years literature review
- Author
-
Gkantaifi, A. Vardas, E. Alongi, F. Tsoukalas, N. Saraireh, H.H. Charalampakis, N. Lövey, J. Hajiioannou, J. Kyrodimos, E. Tsanadis, K. Mauri, D. Christopoulos, C. Iliadis, G. Tolia, M.
- Abstract
Backround: Radiation-induced oral mucositis consists of a series of relatively frequent side effects after head and neck cancer radiotherapy and has an adverse impact on both regular treatment process and the quality of life of patients. Objective: The purpose of the present review is to optimize the current management of radiation-in-duced oral mucositis in head and neck cancer patients. Methods: PubMed database research was performed on articles published since 2015 that demons-trated efficacy in the management of radiation-induced oral mucositis in head and neck cancer pa-tients.The study selection included observational, prospective, comparative, randomized, dou-ble-blind, placebo-controlled or uncontrolled, and retrospective studies, as well as systematic reviews and metanalyses. Results: From the 931 citations obtained from the search, only 94 articles met the inclusion crite-ria, including mucosal protectants, anti-inflammatory agents, growth factors, and various miscellaneous and natural agents. Several methods, including both pharmacological and natural agents, have been proposed for the management of oral mucositis. In addition to the already known interventions with strong evidence, according to the Multinational Association of Supportive Care in Cancer and he International Society of Oral Oncology guidelines, further agents have been used. However, a great number of them lack clear evidence, which surely requires the design of more controlled clinical trials for a better assessment of the ideal methods. Conclusion: The management of oral mucositis constitutes an active area of research. In light of these results, it is aimed to illustrate those treatment strategies that are most effective regarding the treatment approach of oral mucositis. © 2021 Bentham Science Publishers.
- Published
- 2021
6. Patient and family support in the era of fake e-medicine : Food for thought from an international consensus panel
- Author
-
Mauri, D., Kamposioras, K., Tzachanis, D., Tolia, M., Valachis, Antonis, Dambrosio, M., Alongi, F., De Mello, R. A., Lövey, J., Anthoney, A., Christopoulos, C., Saraireh, H. H., Kountourakis, P., Kampletsas, E., Tsali, L., Tsakiridis, T., Kosovitsas, I., Soukovelos, A., Lymperatou, D., Polyzos, N., Zarkavelis, G., Mauri, D., Kamposioras, K., Tzachanis, D., Tolia, M., Valachis, Antonis, Dambrosio, M., Alongi, F., De Mello, R. A., Lövey, J., Anthoney, A., Christopoulos, C., Saraireh, H. H., Kountourakis, P., Kampletsas, E., Tsali, L., Tsakiridis, T., Kosovitsas, I., Soukovelos, A., Lymperatou, D., Polyzos, N., and Zarkavelis, G.
- Published
- 2020
- Full Text
- View/download PDF
7. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
- Author
-
Weller, M, Butowski, N, Tran, DD, Recht, LD, Lim, M, Hirte, H, Ashby, L, Mechtler, L, Goldlust, SA, Iwamoto, F, Drappatz, J, O'Rourke, DM, Wong, M, Hamilton, MG, Finocchiaro, G, Perry, J, Wick, W, Green, J, He, Y, Turner, CD, Yellin, MJ, Keler, T, Davis, TA, Stupp, R, Sampson, JH, Campian, J, Recht, L, Goldlust, S, Becker, K, Barnett, G, Nicholas, G, Desjardins, A, Benkers, T, Wagle, N, Groves, M, Kesari, S, Horvath, Z, Merrell, R, Curry, R, O'Rourke, J, Schuster, D, Mrugala, M, Jensen, R, Trusheim, J, Lesser, G, Belanger, K, Sloan, A, Purow, B, Fink, K, Raizer, J, Schulder, M, Nair, S, Peak, S, Brandes, A, Mohile, N, Landolfi, J, Olson, J, Jennens, R, DeSouza, P, Robinson, B, Crittenden, M, Shih, K, Flowers, A, Ong, S, Connelly, J, Hadjipanayis, C, Giglio, P, Mott, F, Mathieu, D, Lessard, N, Sepulveda, SJ, Lövey, J, Wheeler, H, Inglis, PL, Hardie, C, Bota, D, Lesniak, M, Portnow, J, Frankel, B, Junck, L, Thompson, R, Berk, L, McGhie, J, Macdonald, D, Saran, F, Soffietti, R, Blumenthal, D, André de, SBCM, and Nowak, A
- Abstract
© 2017 Elsevier Ltd Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an EGFRvIII-specific peptide conjugated to keyhole limpet haemocyanin. In the ACT IV study, we aimed to assess whether or not the addition of rindopepimut to standard chemotherapy is able to improve survival in patients with EGFRvIII-positive glioblastoma. Methods In this randomised, double-blind, phase 3 trial, we recruited patients aged 18 years and older with glioblastoma from 165 hospitals in 22 countries. Eligible patients had newly diagnosed glioblastoma confirmed to express EGFRvIII by central analysis, and had undergone maximal surgical resection and completion of standard chemoradiation without progression. Patients were stratified by European Organisation for Research and Treatment of Cancer recursive partitioning analysis class, MGMT promoter methylation, and geographical region, and randomly assigned (1:1) with a prespecified randomisation sequence (block size of four) to receive rindopepimut (500 μg admixed with 150 μg GM-CSF) or control (100 μg keyhole limpet haemocyanin) via monthly intradermal injection until progression or intolerance, concurrent with standard oral temozolomide (150–200 mg/m2for 5 of 28 days) for 6–12 cycles or longer. Patients, investigators, and the trial funder were masked to treatment allocation. The primary endpoint was overall survival in patients with minimal residual disease (MRD; enhancing tumour
- Published
- 2017
8. Report from the OECI Oncology days 2014
- Author
-
Harten, W.H. (Willem H) van, Stanta, G., Bussolati, G., Riegman, P.H.J. (Peter), Hoefler, G., Becker, K.-F. (Karl-Friedrich), Folprecht, G. (Gunnar), Truini, M., Haybaeck, J., Buiga, R., Dono, M., Bagg, A., Guerrero, J.A.L. (J.A. López), Zupo, S., Lemare, F., Lorenzo, F., Goedbloed, N., Razavi, D., Lövey, J., Cadariu, P.A., Rollandi, G.A., Paparo, F., Pierotti, M. (Marco Alessandro), Ciuleanu, T., De Paoli, P., Weiner, G., Saghatchian, M., Lombardo, C. (Claudio), Harten, W.H. (Willem H) van, Stanta, G., Bussolati, G., Riegman, P.H.J. (Peter), Hoefler, G., Becker, K.-F. (Karl-Friedrich), Folprecht, G. (Gunnar), Truini, M., Haybaeck, J., Buiga, R., Dono, M., Bagg, A., Guerrero, J.A.L. (J.A. López), Zupo, S., Lemare, F., Lorenzo, F., Goedbloed, N., Razavi, D., Lövey, J., Cadariu, P.A., Rollandi, G.A., Paparo, F., Pierotti, M. (Marco Alessandro), Ciuleanu, T., De Paoli, P., Weiner, G., Saghatchian, M., and Lombardo, C. (Claudio)
- Abstract
The 2014 OECI Oncology Days was held at the 'Prof. Dr. Ion Chiricuta' Oncology Institute in Cluj, Romania, from 12 to 13 June. The focus of this year's gathering was on developments in personalised medicine and other treatment advances which have made the cost of cancer care too high for many regions throughout Europe.
- Published
- 2014
- Full Text
- View/download PDF
9. Report from the OECI Oncology days 2014
- Author
-
Van Harten, W. H., Stanta, G., Bussolati, G., Riegman, P., Hoefler, G., Becker, K. F., Folprecht, G., Truini, M., Haybaeck, J., Buiga, R., Dono, M., Bagg, A., Guerrero, J. A.López, Zupo, S., Lemare, F., Lorenzo, F., Goedbloed, N., Razavi, D., Lövey, J., Cadariu, P. A., Rollandi, G. A., Paparo, F., Pierotti, M., Ciuleanu, T., De Paoli, P., Weiner, G., Saghatchian, M., Lombardo, Claudio, Van Harten, W. H., Stanta, G., Bussolati, G., Riegman, P., Hoefler, G., Becker, K. F., Folprecht, G., Truini, M., Haybaeck, J., Buiga, R., Dono, M., Bagg, A., Guerrero, J. A.López, Zupo, S., Lemare, F., Lorenzo, F., Goedbloed, N., Razavi, D., Lövey, J., Cadariu, P. A., Rollandi, G. A., Paparo, F., Pierotti, M., Ciuleanu, T., De Paoli, P., Weiner, G., Saghatchian, M., and Lombardo, Claudio
- Abstract
The 2014 OECI Oncology Days was held at the 'Prof. Dr. Ion Chiricuta' Oncology Institute in Cluj, Romania, from 12 to 13 June. The focus of this year's gathering was on developments in personalised medicine and other treatment advances which have made the cost of cancer care too high for many regions throughout Europe.
- Published
- 2014
10. 8533 POSTER First Results of an Uncontrolled, Phase II Trial of Induction Chemotherapy With Cetuximab and Docetaxel-Cisplatin-5FU Followed by Cetuximab+Radiotherapy in the Responders in Locally Advanced Resectable Squamous Cell Cancer of the Head and Neck
- Author
-
Remenar, E., primary, Lövey, J., additional, Koltai, P., additional, Horvath, K., additional, Gödeny, M., additional, and Kasler, M., additional
- Published
- 2011
- Full Text
- View/download PDF
11. 230 oral MODERATE DOSE ESCALATION WITH SINGLE-FRACTION HIGH-DOSE-RATE BRACHYTHERAPY BOOST FOR CLINICALLY LOCALIZED INTERMEDIATE- AND HIGH-RISK PROSTATE CANCER: FIVE-YEAR OUTCOME OF THE FIRST 100 CONSECUTIVELY TREATED PATIENTS
- Author
-
Agoston, P., primary, Major, T., additional, Fröhlich, G., additional, Szabó, Z., additional, Lövey, J., additional, Fodor, J., additional, Kásler, M., additional, and Polgár, C., additional
- Published
- 2011
- Full Text
- View/download PDF
12. DOSIMETRIC COMPARISON BETWEEN PERMANENT VS. HIGHDOSE-RATE PROSTATE BRACHYTHERAPY
- Author
-
Fröhlich, G., primary, Major, T., additional, Agoston, P., additional, Lövey, J., additional, and Polgár, C., additional
- Published
- 2009
- Full Text
- View/download PDF
13. Effect of rH-erythropoietin-a on tumor vasculature and sensitivity to irradiation in epidermoid cancer xenograft
- Author
-
Timar, J., primary, Gillyen, R., additional, Lövey, J., additional, Bereczky, B., additional, and Tovari, J., additional
- Published
- 2004
- Full Text
- View/download PDF
14. Low-dose paclitaxel radiosensitization in locally advanced head and neck cancers
- Author
-
Lövey, J., primary, Koronczay, K., additional, Remenár, É., additional, Csuka, O., additional, and Németh, G., additional
- Published
- 2001
- Full Text
- View/download PDF
15. 552Functional imaging of metastatic lymph nodes by FDG pet
- Author
-
Lövey, J., primary, Trón, L., additional, Gulyás, B., additional, Tóth, E., additional, Molnár, T., additional, and Ésik, O., additional
- Published
- 1996
- Full Text
- View/download PDF
16. Evaluation of the effectiveness of radiotherapy in an Austrian-Hungarian collaboration,A sugárterápiás tevékenység eredményességének külsö minöségi felülvizsgálata osztrák-magyar együttmüködésben
- Author
-
Esik, O., Seitz, W., Lövey, J., Knocke, T. H., Gaudi, I., Németh, G., and Richard Pötter
17. Human recombinant erythropoietin-a increases the efficacy of irradiation in preclinical model,A rekombináns humán erythropoietin-α fokozza a humán laphámrák sugárérzékenysé gét preklinikai modellben
- Author
-
Lövey, J., Kenessey, I., Rásó, E., Dobos, J., Vágó, A., Kásler, M., Futosi, K., Döme, B., Tímár, J., and Tóvári, J.
18. Interstitial boost and altered fractionation as novel approaches to dose escalation in the radiotherapy of glioblastoma multiforme,A szövetközi boost besugárzás és az eltéró frakcionálás, mint új dóziseszkalációs lehetóségek a glioblastoma multiforme sugárkezelésében
- Author
-
Mangel, L., Julow, J., Tibor Major, Hável, J., Lövey, J., Viola, A., Somogyi, A., and Németh, G.
19. Dosimetric evaluation of interstitial high-dose-rate implants for localised prostate cancer,Prosztatadaganatok nagy dózisteljesítményu brachyterápiás 'boost' kezelésének dozimetriai értékelése
- Author
-
Fröhlich, G., Ágoston, P., Lövey, J., Somogyi, A., Fodor, J., and Tibor Major
20. 299: Teletherapy with interstitial brachytherapy for localized prostate cancer: Impact of timing of brachytherapy on the incidence of complications.
- Author
-
Ágoston, P., Fröchlich, G., Major, T., Lövey, J., Somogyi, A., and Fodor, J.
- Subjects
CANCER treatment ,PROSTATE cancer ,DISEASE complications ,RADIOTHERAPY ,GENITOURINARY diseases ,GASTROINTESTINAL diseases - Abstract
Introduction: To investigate whether the timing of brachytherapy (BT) is associated with an increased risk of complications following definitive tele- and brachytherapy for prostate cancer. Methods: Between 2001. and 2006. 133 patients with clinically localized prostate cancer were treated with three dimensional conformal external beam irradiation (median prostate dose: 60 Gy) and interstitial high dose-rate Ir-192 brachytherapy (median dose: 10 Gy). According the timing of brachytherapy patients were divided into two groups: in group A and B BT was delivered between 0-3. week and 4-7. week of teletherapy. Early and late complications data were registered prospectively according to RTOG / EORTC toxicity grading scale. Surgical interventions due to late genitourinary and gastrointestinal complications were also scored separately. Median follow-up time was 34 months (range:12-62). Results: Earlier BT was associated with higher incidence grade 2, 3 late genitourinal complications (P<0,05). Early BT increased also significantly the rate of surgical intervention due to late genitourinal complications (P<0,001). Timing of BT did not have significant impact on either acute genitourinal or gastrointestinal nor late gastrointestinal toxicity rate. Significant correlation was found between late genitourinal and gastrointestinal toxicity (P<0,05). Conclusions: Timing of BT during external beam radiotherapy for localized prostate cancer influencing significantly the risk of late genitourinal complication. Late BT patients experienced fewer urethral complications and surgical interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2008
21. Report from the OECI Oncology Days 2014.
- Author
-
van Harten, W. H., Stanta, G., Bussolati, G., Riegman, P., Hoefler, G., Becker, K. F., Folprecht, G., Truini, M., Haybaeck, J., Buiga, R., Dono, M., Bagg, A., López Guerrero, J. A., Zupo, S., Lemare, F., de Lorenzo, F., Goedbloed, N., Razavi, D., Lövey, J., and Cadariu, P. A.
- Subjects
- *
ONCOLOGY , *CANCER treatment , *MEDICAL care costs , *CONFERENCES & conventions - Abstract
The 2014 OECI Oncology Days was held at the 'Prof. Dr. Ion Chiricuta' Oncology Institute in Cluj, Romania, from 12 to 13 June. The focus of this year's gathering was on developments in personalised medicine and other treatment advances which have made the cost of cancer care too high for many regions throughout Europe. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
22. ECCO Essential Requirements for Quality Cancer Care: Prostate cancer
- Author
-
Peter Hoskin, Alberto Costa, Michael Höckel, Helen Boyle, Philip Poortmans, Rui Medeiros, Maurizio Colecchia, Tiina Saarto, Ken Mastris, Roberto Delgado-Bolton, Kay Leonard, Maurizio Brausi, Raymond Oyen, Marc Beishon, Peter Selby, Ian Banks, Peter Naredi, Theo M. de Reijke, Riccardo Valdagni, József Lövey, Pablo Maroto, Elisabeth Andritsch, Brausi, M., Hoskin, P., Andritsch, E., Banks, I., Beishon, M., Boyle, H., Colecchia, M, Delgado-Bolton, R., Höckel, M., Leonard, K., Lövey, J., Maroto, P., Mastris, K., Medeiros, R., Naredi, P., Oyen, R., de Reijke, T., Selby, P., Saarto, T., Valdagni, R., Costa, A., and Poortmans, P.
- Subjects
Male ,0301 basic medicine ,Palliative care ,media_common.quotation_subject ,Medical Oncology ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Nursing ,Multidisciplinary approach ,Survivorship curve ,Health care ,medicine ,Humans ,Quality (business) ,Pathways ,Socioeconomic status ,Centres ,Quality of Health Care ,media_common ,Patient Care Team ,Multidisciplinary ,business.industry ,Prostatic Neoplasms ,Cancer ,Units ,Hematology ,medicine.disease ,Quality ,3. Good health ,Europe ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,business ,Delivery of Health Care - Abstract
Background ECCO Essential Requirements for Quality Cancer Care (ERQCC) are written by experts representing all disciplines involved in cancer care in Europe. They give oncology teams, patients, policymakers and managers an overview of essential care throughout the patient journey. Prostate cancer Prostate cancer is the second most common male cancer and has a wide variation in outcomes in Europe. It has complex diagnosis and treatment challenges, and is a major healthcare burden. Care must only be a carried out in prostate/urology cancer units or centres that have a core multidisciplinary team (MDT) and an extended team of health professionals. Such units are far from universal in European countries. To meet European aspirations for comprehensive cancer control, healthcare organisations must consider the requirements in this paper, paying particular attention to multidisciplinarity and patient-centred pathways from diagnosis, to treatment, to survivorship.
- Published
- 2020
23. Report from the OECI Oncology days 2014
- Author
-
F Paparo, F Lemare, Darius Razavi, P De Paoli, PA Cadariu, F. De Lorenzo, Johannes Haybaeck, GA Rollandi, Gunnar Folprecht, Giovanni Bussolati, Peter Riegman, JA López Guerrero, Giorgio Stanta, T Ciuleanu, Marco A. Pierotti, Claudio Lombardo, József Lövey, S Zupo, R Buiga, W.H. van Harten, Mauro Truini, A Bagg, M Dono, Karl-Friedrich Becker, Gerald Hoefler, Mahasti Saghatchian, N. Goedbloed, G Weiner, Health Technology & Services Research, Faculty of Behavioural, Management and Social Sciences, van Harten, W, Stanta, Giorgio, Bussolati, G, Riegman, P, Hoefler, G, Becker, K, Folprecht, G, Truini, M, Haybaeck, J, Buiga, R, Dono, M, Bagg, A, López Guerrero, J, Zupo, S, Lemare, F, de Lorenzo, F, Goedbloed, N, Razavi, D, Lövey, J, Cadariu, P, Rollandi, G, Paparo, F, Pierotti, M, Ciuleanu, T, De Paoli, P, Weiner, G, Saghatchian, M, Lombardo, C., and Pathology
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Designation ,organisation ,comprehensive cancer centres ,designation ,accreditation ,personalized medicine ,Comprehensive cancer centres ,Accreditation ,Environnement et pollution ,Clinical decision making ,SDG 3 - Good Health and Well-being ,Internal medicine ,IR-97320 ,medicine ,Tumor biopsy ,METIS-311886 ,business.industry ,comprehensive cancer centre ,Cancer survival ,Conference Report ,Personalized medicine ,Health care delivery ,Cancérologie ,Organisation ,Cancer Radiotherapy ,Day hospital ,business - Abstract
The 2014 OECI Oncology Days was held at the 'Prof. Dr. Ion Chiricuta' Oncology Institute in Cluj, Romania, from 12 to 13 June. The focus of this year's gathering was on developments in personalised medicine and other treatment advances which have made the cost of cancer care too high for many regions throughout Europe., SCOPUS: ar.j, info:eu-repo/semantics/published
- Published
- 2014
24. Application of comprehensive molecular genetic profiling in precision cancer medicine, Hungarian experiences.
- Author
-
Tóth E, Kürönya Z, Soós E, Pintér T, Butz H, Horváth Z, Csernák E, Grolmusz VK, Székely J, Straussz T, Lövey J, Jánvári L, Báthory-Fülöp L, Nagy P, Polgár C, and Patócs A
- Subjects
- Humans, Hungary, Male, Female, Middle Aged, Aged, Adult, Aged, 80 and over, Young Adult, Adolescent, Molecular Targeted Therapy methods, Biomarkers, Tumor genetics, Precision Medicine methods, Neoplasms genetics, Neoplasms drug therapy, Neoplasms therapy, High-Throughput Nucleotide Sequencing methods, Genetic Testing methods
- Abstract
Recent developments in molecular genetic testing methods (e.g. next-generation sequencing [NGS]-panels) largely accelerated the process of finding the most appropriate targeted therapeutic intervention for cancer patients based on molecularly targetable genetic alterations. In Hungary, a centralized approval system following the recommendation of the National Molecular Tumor Board was launched for the coordination of all aspects of comprehensive genetic profiling (CGP) including patient selection and therapy reimbursement., Aim: The study aims to evaluate the clinical benefit of CGP in our Comprehensive Cancer Center Methods and patients: CGP was introduced into our routine clinical practice in 2021. An NGS-based large (> 500 genes) gene panel was used for cases where molecular genetic testing was approved by the National Molecular Tumor Board. From 2021 until August 2023 163 cases were tested. The majority of them were ECOG 0-1 patients with advanced-stage diseases, histologically rare cancer, or cancers with unknown primary tumours., Results: Seventy-four cases (74 of 163, 45%) had clinically relevant genetic alterations. In 34 patients, the identified variants represented an indication for an approved therapy (approved by the Hungarian authorities, on-label indication), while in 40 cases the recommended therapy did not have an approved indication in Hungary for certain tumour types, but off-label indication could be recommended. Based on our CGP results, 24 patients (24/163; 14.7%) received targeted therapy. Treatment duration was between 1 and 60 months. In total 14 (14/163; 8.5% of the tested cases) patients had a positive clinical response (objective response or stable disease) and were treated for more than 16 weeks., Interpretation: NGS-based CGP was successfully introduced in our institution and a significant number of patients benefited from comprehensive genetic tests. Our preliminary results can serve as the starting point of Drug Rediscovery Protocol (DRUP) studies.
- Published
- 2024
- Full Text
- View/download PDF
25. Positive correlation between persistence of medical nutrition therapy and overall survival in patients with head and neck cancer.
- Author
-
Molnár A, Pálfi E, Belák B, Blasszauer C, Reibl D, and Lövey J
- Subjects
- Humans, Cohort Studies, Retrospective Studies, Head and Neck Neoplasms therapy, Nutrition Therapy
- Abstract
Background: Several factors can affect overall survival of head and neck cancer (HNC) patients, including characteristics of the cancer disease and response to treatments. However, patients' nutritional status and the effectiveness of medical nutrition therapy (MNT) can also impact overall survival. The primary goal of our research was to collect real-life data on the use of MNT in HNC patients and to specifically investigate the correlation between survival and the duration of uninterrupted (persistent) nutrition. Method: The data of this retrospective, analytical, cohort study was collected from electronic healthcare records from the Hungarian National Health Insurance Fund Management. Overall, 38,675 HNC patients' data of the period between 2012 and 2021 was used. We applied multi-step exclusions to identify patient groups accurately and to avoid biasing factors. Statistical analysis was done by the Kaplan-Meier method, log-rank test, and Cox regression analysis. Results: Throughout the investigated period 16,871 (64%) patients received MNT therapy out of 26,253 newly diagnosed patients (≥18 years). In terms of the persistence of MNT, we divided the patients into three groups (1-3; 4-6; ≥7-month duration of MNT). When comparing these groups, we found that patients receiving long-term (≥7 months) MNT had a significantly longer overall survival ( p < 0.0001) than those who received MNT for a shorter duration, both in locally advanced and recurrent/metastatic cases. Conclusion: The main outcome of the study is that there is a positive correlation between the persistence of MNT and the overall survival in HNC patients when nutritional intervention lasts several months. It highlights the responsibility of the specialists during the patient journey to use MNT early and to continue its use for as long as it is beneficial to the patients., Competing Interests: AM is employed by Danone Hungary Kft. CB and DR were employed by MedicalScan Kft. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Molnár, Pálfi, Belák, Blasszauer, Reibl and Lövey.)
- Published
- 2024
- Full Text
- View/download PDF
26. [Effect of long-term medical nutrition therapy on the survival of head and neck cancer patients - based on real-world data].
- Author
-
Belák B, Molnár A, Pálfi E, Blasszauer C, Reibl D, and Lövey J
- Subjects
- Humans, Nutritional Status, Medical Oncology, Nutrition Therapy, Head and Neck Neoplasms therapy
- Abstract
At the 45th Congress of ESPEN (The European Society for Clinical Nutrition and Metabolism), we presented for the first time the initial results of our 2023 oncology research, in which we revealed positive correlations between the persistence of medical nutrition therapy and overall survival, in head and neck cancer patients. Patients who received longterm nutrition therapy (≥7 months) had a significantly longer survival (p<0.0001) than those who received only short-term nutrition therapy intervention, i.e., for 1-3 months. The aim, methodology and results of the Hungarian research aroused the interest of the congress participants; therefore, we also publish it in Hungarian in the form of a short notice.
- Published
- 2023
27. Az alacsony testtömegindex és testtömegcsökkenés vizsgálata magyar tüdődaganatos betegek adatainak felhasználásával.
- Author
-
Gálffy G, Molnár A, Blasszauer C, Komka I, Reibl D, and Lövey J
- Subjects
- Body Mass Index, Humans, Hungary, Retrospective Studies, Lung Neoplasms therapy, Weight Loss
- Abstract
During oncological treatments, body mass index (BMI) and weight loss (WL) are important prognostic factors, but can be influenced by nutrition therapy. The aim of the study was to collect data on BMI and WL of patients with lung cancer and on the nutritional therapy influencing malnutrition. In our multicenter, retrospective study involving 1616 patients, data were collected using a questionnaire with 51 questions, and statistical analysis was performed with descriptive, and multivariate analysis methods with IBM SPSS 20 software. According to the method of Martin, based on BMI and WL, patients were ranked on a scale of 0 to 4 (grade 0 24.9%; grade 1 20.7%; grade 2 14.9%; grade 3 22.4%; grade 4 17.0%). Based on this data low BMI and WL may affect survival in 75.1%. In contrast, only 37.6% of patients received nutritional therapy, based on 47 different strategies. The data substituted into the prognostic matrix highlights that weight loss may shorten patients' survival. The 47 strategies indicate that the use of nutritional therapy is inconsistent throughout this patient cohort.
- Published
- 2022
28. Case Report: A Novel Pathomechanism in PEComa by the Loss of Heterozygosity of TP53 .
- Author
-
Butz H, Lövey J, Szentkereszty M, Bozsik A, Tóth E, and Patócs A
- Abstract
Since the introduction of next-generation sequencing, the frequency of germline pathogenic TP53 variants and the number of cases with unusual clinical presentations have been increasing. This has led to the expansion of the classical Li-Fraumeni syndrome concept to a wider cancer predisposition syndrome designated as the Li-Fraumeni spectrum. Here, we present a case with a malignant, metastatic perivascular epithelioid cell tumor (PEComa) of the thigh muscle and a sinonasal carcinoma harboring a novel TP53 germline splice mutation (NM_000546.5:c.97-2A>C). The classical presentation of LFS in the long-since deceased mother and the presence of a germline TP53 variant in the proband suggested a possible familial TP53- related condition. Complex pathological, molecular, and clinical genetic analyses (whole exome sequencing of germline variants, multigene panel sequencing of tumor DNA, Sanger validation, an in vitro functional test on splicing effect, 3D protein modeling, p53 immunohistochemistry, and pedigree analysis) were performed. The in vitro characterization of the splice mutation supported the pathogenic effect that resulted in exon skipping. A locus-specific loss of heterozygosity in the PEComa but not in the sinonasal carcinoma was identified, suggesting the causative role of the splice mutation in the PEComa pathogenesis, because we excluded known pathogenetic pathways characteristic to PEComas ( TSC1/2 , TFE3 , RAD51B ). However, the second hit affecting TP53 in the molecular pathogenesis of the sinonasal carcinoma was not identified. Although PEComa has been reported previously in two patients with Li-Fraumeni syndrome, to the best of our knowledge, this is the first report suggesting a relationship between the aberrant TP53 variant and PEComa., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Butz, Lövey, Szentkereszty, Bozsik, Tóth and Patócs.)
- Published
- 2022
- Full Text
- View/download PDF
29. Chromosomal Aberrations in Blood Lymphocytes as Predictors of Respiratory Function After Stereotactic Lung Irradiation.
- Author
-
Kocsis ZS, Farkas G, Bajcsay A, Kun-Gazda M, Lövey J, Ostoros G, Pócza T, Herein A, Ladányi K, Székely G, Markóczy Z, Takácsi-Nagy Z, Polgár C, and Juranyi Z
- Abstract
Due to the profound difference in radiosensitivity of patients and various side effects caused by this phenomenon, a radiosensitivity marker is needed. Prediction by a marker may help personalise the treatment. In this study, we tested chromosomal aberrations (CA) of in vitro irradiated blood as predictor of pulmonary function decrease of nonsmall cell lung cancer (NSCLC) patients and also compared it with the CAs in the blood of irradiated patients. Peripheral blood samples were taken from 45 lung cancer patients before stereotactic radiotherapy (SBRT) and immediately after the last fraction and 3, 6, 9, 12, 15, 18, 21, and 24 months later. Respiratory function measurements were performed at the same time. Diffusing capacity of lung for carbon monoxide (DLCO), forced vital capacity (FVC), forced expiratory volume in 1 s (FEV1s), and FEV1s/FVC (FEV1%) were monitored. Metaphase preparations of lymphocytes were made with standard procedures, and chromosome aberrations were analysed. In our cohort, the 36-month local relapse-free survival was 97.4%, and the distant metastasis-free survival was 71.5% at 36 months. There was no change in the mean of the pulmonary function tests (PFTs) after the therapy. However, there was a considerable variability between the patients. Therefore, we subtracted the baseline and normalised the PFT values. There were significant decreases at 12-24 months in relative FEV1s and relative FEV1%. The tendentious decrease of the PFTs could be predicted by the in vitro chromosome aberration data. We also found connections between the in vitro and in vivo CA values (i.e., dicentrics plus rings after 3 Gy irradiation predicts dicentric-plus-ring value directly after the radiotherapy/V
54 Gy ( p = 0.001 24.2%)). We found that-after further validation-chromosome aberrations resulted from in vitro irradiation before radiotherapy can be a predictive marker of pulmonary function decrease after lung irradiation., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Kocsis, Farkas, Bajcsay, Kun-Gazda, Lövey, Ostoros, Pócza, Herein, Ladányi, Székely, Markóczy, Takácsi-Nagy, Polgár and Juranyi.)- Published
- 2022
- Full Text
- View/download PDF
30. [Radiotherapy of pancreatic cancer].
- Author
-
Jánváry LZ and Lövey J
- Subjects
- Humans, Pancreatic Neoplasms radiotherapy, Radiation Oncology
- Abstract
The therapy of pancreatic cancer is fundamentally based on surgical removal and chemotherapy. The available evidence and results of publications concerning the application of radiotherapy are controversial. Accordingly, the international guidelines formulated by radiation oncology organizations have paramount interest in this particular pathology. Answers are eagerly awaited in several unclear questions from ongoing, or recently closed, yet unpublished trials. Modern radiotherapy techniques, like stereotactic radiotherapy, or actually less available modalities, like particle therapy or magnetic resonance imaging guided radiotherapy show promising results, as well as combination of radiation with immunotherapy.
- Published
- 2021
31. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
- Author
-
Lee NY, Ferris RL, Psyrri A, Haddad RI, Tahara M, Bourhis J, Harrington K, Chang PM, Lin JC, Razaq MA, Teixeira MM, Lövey J, Chamois J, Rueda A, Hu C, Dunn LA, Dvorkin MV, De Beukelaer S, Pavlov D, Thurm H, and Cohen E
- Subjects
- Adult, Aged, Antibodies, Monoclonal administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, B7-H1 Antigen antagonists & inhibitors, B7-H1 Antigen genetics, Chemoradiotherapy, Cisplatin administration & dosage, Double-Blind Method, Female, Germany, Humans, Male, Middle Aged, Neoplasm Recurrence, Local genetics, Neoplasm Recurrence, Local immunology, Neoplasm Recurrence, Local pathology, Placebos administration & dosage, Progression-Free Survival, Squamous Cell Carcinoma of Head and Neck genetics, Squamous Cell Carcinoma of Head and Neck immunology, Squamous Cell Carcinoma of Head and Neck pathology, Standard of Care, Antibodies, Monoclonal, Humanized administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Neoplasm Recurrence, Local drug therapy, Squamous Cell Carcinoma of Head and Neck drug therapy
- Abstract
Background: Chemoradiotherapy is the standard of care for unresected locally advanced squamous cell carcinoma of the head and neck. We aimed to assess if addition of avelumab (anti-PD-L1) to chemoradiotherapy could improve treatment outcomes for this patient population., Methods: In this randomised, double-blind, placebo-controlled, phase 3 study, patients were recruited from 196 hospitals and cancer treatment centres in 22 countries. Patients aged 18 years or older, with histologically confirmed, previously untreated, locally advanced squamous cell carcinoma of the oropharynx, hypopharynx, larynx, or oral cavity (unselected for PD-L1 status), an Eastern Cooperative Oncology Group performance status score of 0 or 1, and who could receive chemoradiotherapy were eligible. Patients were randomly assigned (1:1) centrally by means of stratified block randomisation with block size four (stratified by human papillomavirus status, tumour stage, and nodal stage, and done by an interactive response technology system) to receive 10 mg/kg avelumab intravenously every 2 weeks plus chemoradiotherapy (100 mg/m
2 cisplatin every 3 weeks plus intensity-modulated radiotherapy with standard fractionation of 70 Gy [35 fractions during 7 weeks]; avelumab group) or placebo plus chemoradiotherapy (placebo group). This was preceded by a single 10 mg/kg avelumab or placebo lead-in dose given 7 days previously and followed by 10 mg/kg avelumab or placebo every 2 weeks maintenance therapy for up to 12 months. The primary endpoint was progression-free survival by investigator assessment per modified Response Evaluation Criteria in Solid Tumors, version 1.1, in all randomly assigned patients. Adverse events were assessed in patients who received at least one dose of avelumab or placebo. This trial is registered with ClinicalTrials.gov, NCT02952586. Enrolment is no longer ongoing, and the trial has been discontinued., Findings: Between Dec 12, 2016, and Jan 29, 2019, from 907 patients screened, 697 patients were randomly assigned to the avelumab group (n=350) or the placebo group (n=347). Median follow-up for progression-free survival was 14·6 months (IQR 8·5-19·6) in the avelumab group and 14·8 months (11·6-18·8) in the placebo group. Median progression-free survival was not reached (95% CI 16·9 months-not estimable) in the avelumab group and not reached (23·0 months-not estimable) in the placebo group (stratified hazard ratio 1·21 [95% CI 0·93-1·57] favouring the placebo group; one-sided p=0·92). The most common grade 3 or worse treatment-related adverse events were neutropenia (57 [16%] of 348 patients in the avelumab group vs 52 [15%] of 344 patients in the placebo group), mucosal inflammation (50 [14%] vs 45 [13%]), dysphagia (49 [14%] vs 47 [14%]), and anaemia (41 [12%] vs 44 [13%]). Serious treatment-related adverse events occurred in 124 (36%) patients in the avelumab group and in 109 (32%) patients in the placebo group. Treatment-related deaths occurred in two (1%) patients in the avelumab group (due to general disorders and site conditions, and vascular rupture) and one (<1%) in the placebo group (due to acute respiratory failure)., Interpretation: The primary objective of prolonging progression-free survival with avelumab plus chemoradiotherapy followed by avelumab maintenance in patients with locally advanced squamous cell carcinoma of the head and neck was not met. These findings may help inform the design of future trials investigating the combination of immune checkpoint inhibitors plus CRT., Funding: Pfizer and Merck KGaA, Darmstadt, Germany., (Copyright © 2021 Elsevier Ltd. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
32. Radiation-Induced Oral Mucositis in Head and Neck Cancer Patients. Five Years Literature Review.
- Author
-
Gkantaifi A, Vardas E, Alongi F, Tsoukalas N, Saraireh HH, Charalampakis N, Lövey J, Hajiioannou J, Kyrodimos E, Tsanadis K, Mauri D, Christopoulos C, Iliadis G, and Tolia M
- Subjects
- Humans, Male, Prospective Studies, Quality of Life, Retrospective Studies, Head and Neck Neoplasms radiotherapy, Stomatitis etiology, Stomatitis therapy
- Abstract
Backround: Radiation-induced oral mucositis consists of a series of relatively frequent side effects after head and neck cancer radiotherapy and has an adverse impact on both regular treatment process and the quality of life of patients., Objective: The purpose of the present review is to optimize the current management of radiation-induced oral mucositis in head and neck cancer patients., Methods: PubMed database research was performed on articles published since 2015 that demonstrated efficacy in the management of radiation-induced oral mucositis in head and neck cancer patients. The study selection included observational, prospective, comparative, randomized, double- blind, placebo-controlled or uncontrolled, and retrospective studies, as well as systematic reviews and metanalyses., Results: From the 931 citations obtained from the search, only 94 articles met the inclusion criteria, including mucosal protectants, anti-inflammatory agents, growth factors, and various miscellaneous and natural agents. Several methods, including both pharmacological and natural agents, have been proposed for the management of oral mucositis. In addition to the already known interventions with strong evidence, according to the Multinational Association of Supportive Care in Cancer and he International Society of Oral Oncology guidelines, further agents have been used. However, a great number of them lack clear evidence, which surely requires the design of more controlled clinical trials for a better assessment of the ideal methods., Conclusion: The management of oral mucositis constitutes an active area of research. In light of these results, it is aimed to illustrate those treatment strategies that are most effective regarding the treatment approach of oral mucositis., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2021
- Full Text
- View/download PDF
33. European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC): Lung cancer.
- Author
-
Berghmans T, Lievens Y, Aapro M, Baird AM, Beishon M, Calabrese F, Dégi C, Delgado Bolton RC, Gaga M, Lövey J, Luciani A, Pereira P, Prosch H, Saar M, Shackcloth M, Tabak-Houwaard G, Costa A, and Poortmans P
- Subjects
- Delivery of Health Care, Europe, Humans, Quality of Health Care, Lung Neoplasms diagnosis, Lung Neoplasms epidemiology, Lung Neoplasms therapy
- Abstract
European Cancer Organisation Essential Requirements for Quality Cancer Care (ERQCC) are written by experts representing all disciplines involved in cancer care in Europe. They give patients, health professionals, managers and policymakers a guide to essential care throughout the patient journey. Lung cancer is the leading cause of cancer mortality and has a wide variation in treatment and outcomes in Europe. It is a major healthcare burden and has complex diagnosis and treatment challenges. Care must only be carried out in lung cancer units or centres that have a core multidisciplinary team (MDT) and an extended team of health professionals detailed here. Such units are far from universal in European countries. To meet European aspirations for comprehensive cancer control, healthcare organisations must consider the requirements in this paper, paying particular attention to multidisciplinarity and patient-centred pathways from diagnosis, to treatment, to survivorship., (Copyright © 2020. Published by Elsevier B.V.)
- Published
- 2020
- Full Text
- View/download PDF
34. Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel.
- Author
-
Mauri D, Kamposioras K, Tzachanis D, Tolia M, Valachis A, Dambrosio M, Alongi F, De Mello RA, Lövey J, Anthoney A, Christopoulos C, Saraireh HH, Kountourakis P, Kampletsas E, Tsali L, Tsakiridis T, Kosovitsas I, Soukovelos A, Lymperatou D, Polyzos N, and Zarkavelis G
- Subjects
- Consensus, Humans, Global Health standards, Telemedicine methods
- Abstract
Competing Interests: Competing interests: None declared.
- Published
- 2020
- Full Text
- View/download PDF
35. ECCO Essential Requirements for Quality Cancer Care: Prostate cancer.
- Author
-
Brausi M, Hoskin P, Andritsch E, Banks I, Beishon M, Boyle H, Colecchia M, Delgado-Bolton R, Höckel M, Leonard K, Lövey J, Maroto P, Mastris K, Medeiros R, Naredi P, Oyen R, de Reijke T, Selby P, Saarto T, Valdagni R, Costa A, and Poortmans P
- Subjects
- Europe, Humans, Male, Medical Oncology, Patient Care Team, Delivery of Health Care, Prostatic Neoplasms, Quality of Health Care
- Abstract
Background: ECCO Essential Requirements for Quality Cancer Care (ERQCC) are written by experts representing all disciplines involved in cancer care in Europe. They give oncology teams, patients, policymakers and managers an overview of essential care throughout the patient journey., Prostate Cancer: Prostate cancer is the second most common male cancer and has a wide variation in outcomes in Europe. It has complex diagnosis and treatment challenges, and is a major healthcare burden. Care must only be a carried out in prostate/urology cancer units or centres that have a core multidisciplinary team (MDT) and an extended team of health professionals. Such units are far from universal in European countries. To meet European aspirations for comprehensive cancer control, healthcare organisations must consider the requirements in this paper, paying particular attention to multidisciplinarity and patient-centred pathways from diagnosis, to treatment, to survivorship., Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest for this paper., (Copyright © 2020 Elsevier B.V. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
36. [Combination of radiation and immunotherapy in cancer treatment].
- Author
-
Lövey J and Polgár C
- Subjects
- Combined Modality Therapy, Humans, Neoplasms immunology, Immunotherapy, Neoplasms radiotherapy, Neoplasms therapy
- Abstract
It is known since the beginning of the 20th century that ionizing radiation has an effect on the immune system. The abscopal effect was well known but extremely rare. However, many study groups performed intensive preclinical research in the field. One of the most prominent recent developments of medical science is the introduction of modern immunotherapy to the treatment of cancer. The widespread use of immunotherapy drew again the attention to the possible role of radiation in conjunction with immunotherapy. There is growing evidence that ionizing radiation may potentiate the effect of immunotherapy. Prospective trials have been launched and the results are very much awaited. But research is booming and new targets of immunotherapy are identified, while we have insufficient knowledge about the underlying biological mechanisms. Therefore, it is highly important that intensive basic and translation research be done and its results should provide sound knowledge to design new clinical trials which, we believe, will lead to better treatment of our patients. In this short review we try to give a snapshot about the current state of the combined clinical use of radiation and immunotherapy.
- Published
- 2019
37. Complex treatment of colorectal liver metastases Consensus Conference, Budapest, 5th April 2019
- Author
-
András C, Bartek P, Battyáni I, Bezsilla J, Bodoky G, Bogner B, Bursics A, Csőszi T, Damjanovich L, Dank M, Dankovics Z, Deák PÁ, Dede K, Doros A, Dudás I, Györke T, Hahn O, Hartmann E, Hitre E, Horváth Z, Imre M, Kalmár Nagy K, Káposztás Z, Kóbori L, Kupcsulik P, Landherr L, Lóderer Z, Mangel L, Máthé Z, Mersich T, Mezei K, Mohos E, Oláh A, Pajor P, Palkó A, Pápai Z, Papp A, Patyánik M, Petri A, Révész J, Ruzsa Á, Schlachter K, Sikorszki L, Sipőcz I, Székely E, Szijártó A, Torday L, Tóth LB, Dósa E, Harsányi L, István G, Landherr L, Lázár G, Lövey J, Schaff Z, Szűcs Á, and Vereczkei A
- Published
- 2019
- Full Text
- View/download PDF
38. Combination of pentoxifylline and α-galactosylceramide with radiotherapy promotes necro-apoptosis and leukocyte infiltration and reduces the mitosis rate in murine melanoma.
- Author
-
Madera-Sandoval RL, Tóvári J, Lövey J, Ranđelović I, Jiménez-Orozco A, Hernández-Chávez VG, Reyes-Maldonado E, and Vega-López A
- Subjects
- Animals, Cell Line, Tumor, Male, Mice, Apoptosis drug effects, Apoptosis radiation effects, Chemoradiotherapy, Galactosylceramides pharmacology, Leukocytes metabolism, Leukocytes pathology, Melanoma, Experimental metabolism, Melanoma, Experimental pathology, Melanoma, Experimental therapy, Mitosis drug effects, Mitosis radiation effects, Pentoxifylline pharmacology
- Abstract
Despite the success for the treatment of melanoma such as targeted molecular therapy, the use of such treatments are expensive For this reason, this study was carried out to explore the anti-cancer properties of available drugs that are able to modify the melanoma prognosis. The study was conducted in two phases: Evaluation of pharmacological effects of pentoxifylline (PTX) administered above (60 mg/kg) which is the therapeutic dose that is aimed at reducing the side-effect of radiotherapy, and of α- galactosylceramide (GalCer) administered at 100 μg/kg, as well as their combination using a murine model (BDF1 mice) of melanoma cell line (B16-F1, ATCC). For the radiotherapy phase, 9 Gy was applied in the tumor area, before (3 days), during (30 min) and after (3 days) the PTX + GalCer treatment. In both study phases, the mitosis rate, leukocyte infiltration and necro-apoptosis were assessed using histological and immunohistochemical approach and tumor volume evaluation as biomarkers. All treatments showed good prognosis results estimated as reduction of mitosis rate (PTX + GalCer after radiotherapy and GalCer), increased leukocyte infiltrate (PTX + GalCer after radiotherapy and GalCer) and necro-apoptosis augmentation (PTX + GalCer after radiotherapy and radiotherapy control). Nevertheless, a lower development of tumor volume was found in GalCer treatment. In this way, it is possible to suggest that the integrated treatment with immuno-stimulators such as GalCer, plus drug used for peripheral vascular disease (PTX) after radiotherapy is probably an alternative for controlling aggressive melanoma in murine model., (Copyright © 2019 Elsevier GmbH. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
39. Local immune parameters as potential predictive markers in head and neck squamous cell carcinoma patients receiving induction chemotherapy and cetuximab.
- Author
-
Ladányi A, Kapuvári B, Papp E, Tóth E, Lövey J, Horváth K, Gődény M, and Remenár É
- Subjects
- Adult, Aged, Biomarkers, Tumor analysis, Biomarkers, Tumor metabolism, Biopsy, Female, Head and Neck Neoplasms drug therapy, Humans, Induction Chemotherapy, Male, Middle Aged, Prognosis, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck drug therapy, Antineoplastic Agents, Immunological therapeutic use, Cetuximab therapeutic use, Dendritic Cells immunology, Head and Neck Neoplasms immunology, Lymphocytes immunology, Lymphocytes physiology, Programmed Cell Death 1 Receptor metabolism, Squamous Cell Carcinoma of Head and Neck immunology
- Abstract
Background: The aim of this study was to determine whether tumor-associated immune cells may predict response to therapy and disease outcome in head and neck squamous cell carcinoma (HNSCC) patients receiving induction chemotherapy and cetuximab., Methods: Paraffin-embedded pretreatment biopsy samples from 45 patients with stage III-IV resectable HNSCC were investigated retrospectively by immunohistochemistry for density of different immune cell types based on expression of CD8, FOXP3, CD134, CD137, PD-1, CD20, NKp46, dendritic cell lysosomal-associated membrane protein (DC-LAMP), CD16, CD68, and myeloperoxidase. Results were analyzed for possible correlations with clinicopathologic parameters, response to therapy, and survival., Results: Of the immune cell types studied, we found significant association with response to induction chemotherapy only in the case of DC-LAMP
+ mature dendritic cells and PD-1+ lymphocytes; density of DC-LAMP+ cells also correlated with progression-free survival., Conclusion: DC-LAMP+ mature dendritic cells and PD-1+ cells may be implicated in response to induction chemotherapy and cetuximab in HNSCC patients., (© 2018 Wiley Periodicals, Inc.)- Published
- 2019
- Full Text
- View/download PDF
40. [Stereotactic body radiotherapy of liver metastasis: early experience].
- Author
-
Földi G, Polgár C, Zongor Z, Melles-Bencsik B, Stelczer G, Madaras B, Pintér T, Jederán É, and Lövey J
- Subjects
- Chemoembolization, Therapeutic, Humans, Treatment Outcome, Liver Neoplasms radiotherapy, Liver Neoplasms secondary, Neoplasm Metastasis radiotherapy, Radiosurgery
- Abstract
Recently the prevalence of oligometastatic patients is increasing. A common site of distant spread is the liver. The standard of care is curative surgical resection, however, the resecability rate is only 10-20%. Alternatively, radiofrequency ablation (RFA) or transarterial chemoembolization (TACE) may be used. Stereotactic ablative body radiotherapy (SABRT) makes it possible to deliver curative radiation dose without radiation injury to the healthy liver tissue. We delivered SABRT to three patients with inoperable hepatic metastases. The primary tumors were rectal (2) and lung (1). The dose was 3x20 Gy every other day. We observed one grade 1 side effect. All the metastases showed complete remission and no local recurrence or late side effect occurred during the one year of follow-up. One patient is tumor-free, one has stable disease, in one patient two new hepatic metastases appeared and receives chemo-biological therapy. SABRT of liver metastases is safe and highly effective. It can be expected that in the near future it will become one of the standard treatments of hepatic tumors.
- Published
- 2018
41. ECCO essential requirements for quality cancer care: Oesophageal and gastric cancer.
- Author
-
Allum W, Lordick F, Alsina M, Andritsch E, Ba-Ssalamah A, Beishon M, Braga M, Caballero C, Carneiro F, Cassinello F, Dekker JW, Delgado-Bolton R, Haustermans K, Henning G, Hutter B, Lövey J, Netíková IŠ, Obermannová R, Oberst S, Rostoft S, Saarto T, Seufferlein T, Sheth S, Wynter-Blyth V, Costa A, and Naredi P
- Subjects
- Delivery of Health Care methods, Delivery of Health Care organization & administration, Europe, Humans, Medical Oncology methods, Medical Oncology organization & administration, Quality of Health Care, Delivery of Health Care standards, Esophageal Neoplasms therapy, Medical Oncology standards, Stomach Neoplasms therapy
- Abstract
Background: ECCO essential requirements for quality cancer care (ERQCC) are checklists and explanations of organisation and actions that are necessary to give high-quality care to patients who have a specific type of cancer. They are written by European experts representing all disciplines involved in cancer care. ERQCC papers give oncology teams, patients, policymakers and managers an overview of the elements needed in any healthcare system to provide high quality of care throughout the patient journey. References are made to clinical guidelines and other resources where appropriate, and the focus is on care in Europe., Oesophageal and Gastric: ESSENTIAL REQUIREMENTS FOR QUALITY CARE: CONCLUSION: Taken together, the information presented in this paper provides a comprehensive description of the essential requirements for establishing a high-quality OG cancer service. The ERQCC expert group is aware that it is not possible to propose a 'one size fits all' system for all countries, but urges that access to multidisciplinary units or centres must be guaranteed for all those with OG cancer., (Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
42. ECCO essential requirements for quality cancer care: Melanoma.
- Author
-
Wouters MW, Michielin O, Bastiaannet E, Beishon M, Catalano O, Del Marmol V, Delgado-Bolton R, Dendale R, Trill MD, Ferrari A, Forsea AM, Kreckel H, Lövey J, Luyten G, Massi D, Mohr P, Oberst S, Pereira P, Prata JPP, Rutkowski P, Saarto T, Sheth S, Spurrier-Bernard G, Vuoristo MS, Costa A, and Naredi P
- Subjects
- Delivery of Health Care methods, Delivery of Health Care organization & administration, Europe, Humans, Medical Oncology methods, Medical Oncology organization & administration, Quality of Health Care, Delivery of Health Care standards, Medical Oncology standards, Melanoma therapy
- Abstract
Background: ECCO essential requirements for quality cancer care (ERQCC) are explanations and descriptions of challenges, organisation and actions that are necessary to give high-quality care to patients who have a specific type of cancer. They are written by European experts representing all disciplines involved in cancer care. ERQCC papers give oncology teams, patients, policymakers and managers an overview of the elements needed in any healthcare system to provide high quality of care throughout the patient journey. References are made to clinical guidelines and other resources where appropriate, and the focus is on care in Europe., Melanoma: ESSENTIAL REQUIREMENTS FOR QUALITY CARE: CONCLUSION: Taken together, the information presented in this paper provides a comprehensive description of the essential requirements for establishing a high-quality service for melanoma. The ERQCC expert group is aware that it is not possible to propose a 'one size fits all' system for all countries, but urges that access to multidisciplinary teams and specialised treatments is guaranteed to all patients with melanoma., (Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
43. [Stereotactic ablative body radiotherapy (SABRT) for locally advanced pancreatic cancer. Case report and review of literature].
- Author
-
Földi G, Zongor Z, Polgár C, Stelczer G, Madaras B, Andi J, and Lövey J
- Subjects
- Aged, Disease-Free Survival, Humans, Hungary, Magnetic Resonance Imaging methods, Male, Neoplasm Invasiveness pathology, Neoplasm Staging, Pancreatic Neoplasms diagnostic imaging, Prognosis, Risk Assessment, Survival Analysis, Treatment Failure, Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Neoadjuvant Therapy methods, Pancreatic Neoplasms pathology, Pancreatic Neoplasms surgery, Radiosurgery methods
- Abstract
Pancreatic cancer has one of the worst outcomes among malignant tumors. At the time of diagnosis only 20% of the cases are resectable and 30-50% are locally advanced, when curative intervention cannot be performed. After resection local relapse occurs in 20-60%, and in 30% it is the reason of death. This latter highlights the importance of local control. However, there have been no convincing results with conformal radiation therapy and radiochemotherapy yet. Adjuvant radiochemotherapy has been settled into the routine in the US, but not in Europe and Asia and only sporadic data are available about neoadjuvant radiotherapy. Based on the result of recent studies, conformal radiation therapy does not seem to become part of the standard treatment of locally advanced disease. Radiation resistance, long treatment time and incompatibility with the most advanced chemotherapy regimens may make conformal radiotherapy ineffective. Stereotactic ablative body radiotherapy (SABRT) when a limited target volume is irradiated in few fractions, with high precision and high biological effective dose, is ablative for the tumor and could be a possible solution for this issue. In our report, we describe to our knowledge the first SABRT for locally advanced pancreatic cancer in Hungary and give a short literature review.
- Published
- 2017
44. [Nutrition therapy of cancer patients].
- Author
-
Lövey J
- Subjects
- Cachexia etiology, Cachexia physiopathology, Humans, Hungary, Malnutrition etiology, Malnutrition physiopathology, Neoplasms diagnosis, Neoplasms therapy, Quality of Life, Risk Assessment, Sarcopenia etiology, Sarcopenia physiopathology, Treatment Outcome, Cachexia therapy, Malnutrition therapy, Neoplasms complications, Nutrition Therapy methods, Sarcopenia therapy
- Abstract
The majority of cancer patients becomes malnourished during the course of their disease. Malnutrition deteriorates the efficiency of all kinds of oncologic interventions. As a consequence of it, treatment-related toxicity increases, hospital stay is lengthened, chances of cure and survival as well as the quality of life of the patients worsen. Nutritional status therefore influences all aspects of outcome of oncology care. In spite of this the use of nutritional therapy varies across health care providers but its application is far from being sufficient during active oncology interventions as well as rehabilitation and supportive care. It threatens not only the outcome and quality of life of cancer patients but also the success of oncologic treatments which often demand high input of human and financial resources. Meanwhile application of nutritional therapy is legally regulated in Hungary and a very recent update of the European guideline on cancer patient nutrition published in 2017 is available. Moreover, cost effectiveness of nutritional therapy has been proven in a number of studies. In this review we present the basics of nutritional therapy including nutritional screening and evaluation, nutritional plan, the role of nutrition support teams, oral, enteral and parenteral nutrition, the use of different drugs and special nutrients and the follow-up of the patients.
- Published
- 2017
45. [Current questions in the radiotherapy of lymphoproliferative tumors].
- Author
-
Lövey J
- Subjects
- Hodgkin Disease radiotherapy, Humans, Lymphoma, Large B-Cell, Diffuse radiotherapy, Radiotherapy, Intensity-Modulated, Lymphoproliferative Disorders radiotherapy, Radiotherapy
- Abstract
Radiation therapy traditionally plays a major role in the treatment of lymphoproliferative diseases. Diagnostics and treatment of these tumors improved tremendously in the recent decades. Molecular diagnostics is able to discriminate its subtypes more precisely than ever and opens the possibility of the introduction of targeted medicines. Imaging, especially functional imaging now has an established role in forming treatment strategy. Radiation therapy showed substantial technical development too. As a consequence of these, the role, dose and technique of radiotherapy changes instantly. In this short review we discuss situations which clinicians, both hemato-oncologists and radiation oncologist may face day by day. These are: the changing role of radiation therapy in early Hodgkin's disease, including dose and filed size reduction and PET-driven radiation therapy; the use of radiation in advanced Hodgkin's disease; the role of radiation therapy of diffuse large B-cell lymphoma in the light of the use of rituximab; and finally the use of modern radiation therapy techniques like intensity-modulated radiation therapy or particle therapy.
- Published
- 2017
46. [Curative radiotherapy of early-stage lung cancer using respiratory motion compensation].
- Author
-
Szilágyi A, Pócza T, Polgár C, Major T, Bajcsay A, and Lövey J
- Subjects
- Combined Modality Therapy, Humans, Lung Neoplasms mortality, Neoplasm Staging, Radiotherapy Dosage, Lung Neoplasms radiotherapy, Radiotherapy methods
- Abstract
In this paper we present our early experience with a method for the management of respiratory motion in radiotherapy for early-stage lung cancer. Forty-six patients were irradiated with a total dose of 60 Gy. Tumor response on control CT, survival, local and distant progression as well as early and late side effects were registered. Complete and partial remission, stable and progressive disease was 17 (37.0%), 15 (32.6%), 11 (23.9%) and 3 (6.5%). Isolated local recurrence and distant metastasis appeared in 4 (8.7%) and 2 (4.3%) cases, while simultaneous local and distant progression was diagnosed in 3 (6.5%) patients. The probability of 2-year local recurrence-free, progression-free, and overall survival was 76.8%, 64.0%, and 83.2%. Grade 1 (G1) and G2 early side effects occurred at 15 (32.6%) and 3 (6.5%) patients without ≥G3 side effects. G1 and G2 late side effects were observed in 10 (21.7%) and 7 (15.2%) cases. G1-2 post-irradiation fibrosis occurred in 11 (23.9%) cases. Twenty months after the irradiation, G5 respiration failure was developed in one patient. The implemented technique of respiratory motion management for the radiotherapy of early-stage lung cancer resulted in promising local freedom from relapse and survival with favorable side effect profile. Further follow-up is needed to assess longterm side effects and survival results.
- Published
- 2016
47. [Imaging protocols for the management of respiratory motions in the radiotherapy planning for early stage lung cancer patients].
- Author
-
Pócza T, Pesznyák C, Lövey J, Bajcsay A, Szilágyi A, Almády B, Major T, and Polgár C
- Subjects
- Aged, Aged, 80 and over, Equipment Design, Female, Humans, Hungary, Lung Neoplasms pathology, Lung Neoplasms radiotherapy, Male, Middle Aged, Neoplasm Staging, Radiotherapy Dosage, Tumor Burden, Lung Neoplasms diagnostic imaging, Lung Neoplasms physiopathology, Radiotherapy Planning, Computer-Assisted instrumentation, Radiotherapy Planning, Computer-Assisted methods, Respiratory Mechanics, Tomography, X-Ray Computed instrumentation, Tomography, X-Ray Computed methods
- Abstract
The aim of our work is to present the imaging techniques used at the National Institute of Oncology for taking into consideration the breathing motion at radiation therapy treatment planning. Internationally recommended imaging techniques, such as 4D CT, respiratory gating and ITV (Internal Target Volume) definition were examined. The different imaging techniques were analysed regarding the delivered dose during imaging, the required time to adapt the technique, and the necessary equipment. The differences in size of PTVs (Planning Target Volume) due to diverse volume defining methods were compared in 5 cases. For 4D CT breath monitoring is crucial, which requires special equipment. To decrease the relatively high exposure of 4D CT it is possible to scan only a few predefined breathing phases. The possible positions of the tumour can be well approximated with CT scans taken in the inhale maximum, the exhale maximum and in intermediate phase. The intermediate phase can be exchanged with an ordinary CT image set, and the extreme phase CT images can be ensured by given verbal instructions for the patient. This way special gating equipment is not required. Based on these 3 breathing phases an ITV can be defined. Using this ITV definition method the margin between the CTV (Clinical Target Volume) and the PTV can be reduced by 1 cm. Using this imaging protocol PTV can be reduced by 30%. A further 10% PTV reduction can be achieved with respiratory gating. In the routine clinical practice respiratory motion management with a 3-phase CT-imaging protocol the PTV for early-stage lung cancer can be significantly reduced without the use of 4D CT and/or respiratory gating. For special, high precision treatment techniques 4D CT is recommended.
- Published
- 2015
48. Report from the OECI Oncology Days 2014.
- Author
-
van Harten W, Stanta G, Bussolati G, Riegman P, Hoefler G, Becker K, Folprecht G, Truini M, Haybaeck J, Buiga R, Dono M, Bagg A, López Guerrero J, Zupo S, Lemare F, de Lorenzo F, Goedbloed N, Razavi D, Lövey J, Cadariu P, Rollandi G, Paparo F, Pierotti M, Ciuleanu T, De Paoli P, Weiner G, Saghatchian M, and Lombardo C
- Abstract
The 2014 OECI Oncology Days was held at the 'Prof. Dr. Ion Chiricuta' Oncology Institute in Cluj, Romania, from 12 to 13 June. The focus of this year's gathering was on developments in personalised medicine and other treatment advances which have made the cost of cancer care too high for many regions throughout Europe.
- Published
- 2014
- Full Text
- View/download PDF
49. [Selective 12-lipoxygenase inhibition potentiates the effect of radiation on human prostate cancer cells in vitro and in vivo].
- Author
-
Lövey J, Nie D, Tóvári J, Kenessey I, Kandouz M, Tímár J, Kásler M, and Honn KV
- Subjects
- Cell Line, Tumor radiation effects, Cell Survival radiation effects, Disease Progression, Humans, Male, Prostatic Neoplasms pathology, Receptors, Eicosanoid drug effects, Xenograft Model Antitumor Assays, Apoptosis radiation effects, Arachidonate 12-Lipoxygenase metabolism, Lipoxygenase Inhibitors pharmacology, Prostatic Neoplasms radiotherapy, Radiation Tolerance drug effects, Receptors, Eicosanoid metabolism
- Abstract
Prostate cancer is one of the leading cancer types in males in the developed world. Radiotherapy is a major method in the curative treatment of prostate cancer however, up to 30% of the patients experience local relapse. Arachidonic acid metabolites have been shown to have important role in cancer. 12-lipoxygenase (12-LOX) has been proven to significantly influence prostate cancer progression, by apoptosis regulation and by promoting cancer cell survival. In this study we examined whether 12-LOX inhibition may increase radiation sensitivity of prostate cancer cells in vitro and in vivo. Prostate cancer cell lines were treated with 12-LOX inhibitors, different doses of radiation and the combination of 12-LOX inhibitors and radiation. We measured the effect of these treatments through clonogenic survival and apoptosis in vitro and tumor growth in vivo in a tumor xenograft model. 12-LOX inhibition and radiation both increased apoptosis and decreased clonogenic survival of prostate cancer cell lines in vitro. Combined treatment resulted in a supra-additive effect in vitro. In vivo both 12-LOX inhibition and radiotherapy caused delay in growth of the xenograft tumors but the combined treatment resulted in the strongest growth inhibition. The presented data prove that 12-LOX and its metabolite 12(S)-HETE have a major role in prostate cancer cell progression and radiosensitivity. We have shown by different methods in vitro and in vivo that inhibition of 12-LOX activity significantly sensitizes prostate cancer cells to radiation. Therefore we can state that 12-LOX inhibitors are promising compounds to be developed to become a new class of clinical radiation sensitizers in prostate cancer.
- Published
- 2014
50. [In memory of Professor Dr. György Nemeth (1935–2014)].
- Author
-
Lövey J and Sauer R
- Subjects
- History, 20th Century, History, 21st Century, Hungary, Radiation Oncology history
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.